Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Cubist buys Calixa for $92.5mm cash, plus potential earn-outs

Executive Summary

Acute care company Cubist Pharmaceuticals is acquiring private cephalosporin developer Calixa Therapeutics for $92.5mm in cash, plus up to $310mm in potential development, regulatory, and commercial milestones for products incorporating Calixa's CXA101, a bacterial cell wall synthesis inhibitor in Phase II for complicated urinary tract infection (cUTI).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Includes Contract
    • Full Acquisition
    • Payment Includes Cash
    • Includes Earnout
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register